Regeneron Pharma Q2 Earnings Top Estimates with Record Sales Growth

SentiSense · Published · Updated

Regeneron Pharmaceuticals reported Q2 2026 earnings that surpassed estimates, with a 17% revenue increase driven by record sales of Dupixent, EYLEA HD...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis